OPEN ACCESS

Short-term effectiveness of high-load compared with low-load strengthening exercise on self-reported function in patients with hypermobile shoulders: a randomised controlled trial

Behnam Liaghat ,[1] Søren T Skou ,[1,2] Jens Søndergaard ,[3] Eleanor Boyle ,[1] Karen Søgaard ,[1,4] Birgit Juul-Kristensen [1]

► Additional supplemental material is published online only. To view, please visit the journal online (http://dx.doi.org/10.1136/bjsports-2021-105223).

[1]Department of Sports Science and Clinical Biomechanics, University of Southern Denmark, Odense, Denmark
[2]Department of Physiotherapy and Occupational Therapy, Næstved-Slagelse-Ringsted Hospitals, Slagelse, Denmark
[3]Department of Public Health, University of Southern Denmark, Odense, Denmark
[4]Department of Clinical Research, University of Southern Denmark, Odense, Denmark

Correspondence to
Dr Behnam Liaghat, Department of Sports Science and Clinical Biomechanics, University of Southern Denmark, Odense, Denmark;
bliaghat@health.sdu.dk

Accepted 17 May 2022

Check for updates

© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

To cite: Liaghat B, Skou ST, Søndergaard J, *et al*. *Br J Sports Med* Epub ahead of print: [*please include* Day Month Year]. doi:10.1136/bjsports-2021-105223

ABSTRACT

Objectives To investigate the short-term effectiveness of high-load versus low-load strengthening exercise on self-reported function in patients with hypermobility spectrum disorder (HSD) and shoulder symptoms.

Methods A superiority, parallel-group, randomised trial (balanced block randomisation, electronic concealment) including adult patients (n=100) from primary care with HSD and shoulder pain and/or shoulder instability ≥3 months. Patients received 16 weeks of shoulder exercises (three sessions/week): HEAVY (n=50, full-range, high-load, supervised twice/week) or LIGHT (n=50, neutral/mid-range, low-load, supervised three times). The primary outcome was the 16-week between-group difference in self-reported function measured with the Western Ontario Shoulder Instability Index (WOSI, scale 0–2100, 0=best, minimal important difference 252 points). Secondary outcomes were self-reported measures including quality of life and clinical tests including shoulder muscle strength and range of motion. An intention-to-treat analysis with multiple imputation was conducted by a blinded biostatistician using linear regression.

Results 93 of 100 patients (93%) completed the 16-week evaluation. The mean WOSI score between-group difference significantly favoured HEAVY (−174.5 points, 95% CI −341.4 to −7.7, adjusted for age, sex, baseline score, clustering around clinic). The secondary outcomes were inconclusive, but patients in HEAVY were less likely to have a positive shoulder rotation test >180°, and more likely to rate an important improvement in physical symptoms. There were no serious adverse events, but HEAVY was associated with more transient muscle soreness (56% vs 37%) and headaches (40% vs 20%).

Conclusion High-load shoulder strengthening exercise was statistically superior to low-load strengthening exercise for self-reported function at 16 weeks and may be used in primary care to treat patients with HSD and shoulder pain and/or instability to improve shoulder function in the short term. Further studies are needed to confirm the clinical relevance, and patients should be supported to manage associated minor adverse events.

Trial registration number NCT03869307.

WHAT IS ALREADY KNOWN ON THIS TOPIC

⇒ Four out of five patients with hypermobility spectrum disorder (HSD) experience symptoms in the shoulder joint. However, evidence for treatment is sparse.

WHAT THIS STUDY ADDS

⇒ For patients with HSD and shoulder pain and/or shoulder instability in primary care, a supervised, progressive high-load shoulder strengthening exercise programme (full-range, open kinetic chain) resulted in greater self-reported improvements in shoulder function than less supervised and less progressive low-load exercises (neutral to midrange) at 16 weeks.

⇒ More than two-thirds of patients receiving high-load strengthening exercise improved shoulder function above the threshold for minimal important difference, and 64% reported an important improvement in physical symptoms postintervention. The exercise programme was associated with transient muscle soreness and headache.

HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE AND/OR POLICY

⇒ The high-load shoulder strengthening exercise programme may be used in patients with HSD and shoulder symptoms in primary care to improve function and reduce shoulder symptoms in the short term.

⇒ Further studies are needed to confirm the clinical relevance and the long-term effectiveness. Clinicians should pay attention to and help manage associated minor adverse events.

INTRODUCTION

Joint hypermobility is defined as the ability to move the joints beyond the normal range of motion, with an estimated prevalence of 2%–57%, depending on race, sex and diagnostic criteria.[1 2] Joint hypermobility may be advantageous in activities and sports where high flexibility is required.[3] However, it may be symptomatic with, for example, chronic/recurrent pain, joint instability, musculoskeletal complaints, fatigue and disability, resulting in decreased ability to participate in daily activities, increased psychological problems and poor health-related quality of life. [3–7] This symptomatic clinical entity is termed hypermobility spectrum disorder (HSD).[8]

Br J Sports Med: first published as 10.1136/bjsports-2021-105223 on 1 June 2022. Downloaded from http://bjsm.bmj.com/ on July 21, 2022 by guest. Protected by copyright.

Remarkably, four out of five people with HSD experience symptoms in the shoulder joint[3 9–11] with profound consequences in daily life.[4 5] Recent studies have reported altered scapular kinematics, imbalanced electromyographic scapular muscle activity and increased humeral head translation in patients with HSD and multidirectional shoulder instability.[12 13] However, there is no gold standard management, and no studies have focused on treatments of the shoulder for this patient group.[14–17] Generally, an important and effective component of exercise interventions for persistent shoulder complaints—such as rotator cuff tendinopathy and anterior or multidirectional glenohumeral instability—aims to improve the function of the scapular stabilising muscles and rotator cuff muscles.[18–20] Furthermore, high-load strengthening exercise has proven to be particularly effective in increasing muscle strength of the global muscles and stiffness of the tendons.[21 22] Since patients with HSD often display strength impairments in the shoulder and decreased musculoskeletal tissue stiffness,[23 24] it is anticipated that they may benefit from the effects of high-load strengthening to improve active joint stability.

Many clinicians use low-load strengthening exercise, hesitating to use high-load strengthening exercise for patients with HSD due to uncertainty about patient safety and treatment effectiveness and because current guidelines recommend against high-load strengthening.[25] Our recent feasibility study on HSD and shoulder symptoms showed that patients could tolerate a 16-week high-load shoulder strengthening programme, with clinical benefits in self-reported shoulder function and objective clinical measures.[26]

The current randomised controlled trial (RCT) aimed to compare the short-term effectiveness of high-load versus low-load shoulder strengthening exercise on self-reported function in patients with HSD and persistent shoulder symptoms. Our primary hypothesis was that high-load shoulder strengthening exercise was superior to low-load exercise (standard care).

METHODS

Design and setting

We conducted a two-group, multicentre, superiority RCT where patients with HSD and shoulder symptoms were recruited from primary care within the Region of Southern Denmark, representing a general patient population in Denmark, between March 2019 and September 2020, with the primary endpoint being postintervention at 16-week follow-up. A total of 23 physiotherapists were chosen to deliver both interventions after receiving a 3-hour training programme. We ensured fidelity by controlling exercise logs, controlling patient payments from the university office to the clinics (no patients received more than the planned sessions: up to 32 for the intervention group and 3 for the comparator), and we controlled how many dumbbells we gave to the clinics. The trial was prospectively registered on ClinicalTrials.gov, and the trial protocol has previously been published elsewhere.[27]

A project manager was responsible for randomisation procedures and practical management of the project. Outcome assessments were completed at two sites by one of four blinded physiotherapists trained in study procedures but not otherwise involved in the project.

Participants

Patients were eligible for inclusion if aged 18–65 and fulfilling the generalised HSD (G-HSD) or historical HSD (H-HSD) criteria.[8 28] The criteria for HSD included musculoskeletal manifestations (ie, chronic shoulder pain and/or shoulder instability symptoms for at least 3 months without any cut-off for symptom intensity[27]) and the presence of generalised joint hypermobility (GJH), which was established using the Beighton score (cut-point of 4 for men of all ages and women ≥50 years and 5 for women <50 years).[28] For H-HSD, a 1-point lower Beighton score was accepted if the patient had a positive 5-part Questionnaire (5PQ) (cut-point of 2).[29] No shoulder laxity/instability tests were used as inclusion criteria to avoid false negative results due to patients' other symptoms.

The exclusion criteria were clinically suspected referred pain from the cervical spine decided by the referring general practitioner; diagnosis of systemic inflammatory rheumatic diseases, connective tissue diseases (except hypermobile Ehlers-Danlos Syndrome) and/or neurological diseases; pregnancy or childbirth within the past year or planning to get pregnant during the trial period (due to increased levels of relaxin); shoulder surgery within the last year or inability to speak or understand Danish, comply with the trial protocol or provide informed consent. After trial commencement, we added to the exclusion criteria steroid injection in the affected shoulder within 3 months to ascertain that the injection effect had diminished. However, no patients recruited prior to this change had received steroid injections within 3 months.

All patients answered an online pre-screening questionnaire at the initial eligibility assessment, including the 5PQ[29] and questions about shoulder symptoms via REDCap. The first author physically screened potentially eligible patients with shoulder symptoms using the Beighton tests[28 30] to classify GJH and later diagnose the patients with HSD. If eligible, patients consenting to participate were baseline tested and subsequently randomised. They were offered their first intervention session, preferably within 1 week after baseline testing or as close to that as practically possible. Patients were told that the trial compared two different exercise protocols to increase shoulder muscle function without revealing the direction of our hypothesis to control for expectation and performance bias.

Randomisation, allocation concealment and blinding

The allocation sequence was computer-generated with balanced block randomisation (block size 4–6), set up by an external data manager. Immediately following the baseline testing, the project manager completed the randomisation automatically in REDCap. To ensure allocation concealment, everyone was blinded to block sizes and unaware of the following assignment in the allocation sequence. The first author and outcome assessors were kept blinded from group allocation. The physiotherapists responsible for delivering interventions were not blinded to which treatment the patients had been allocated. A biostatistician (EB) performed the intention-to-treat (ITT) analyses of the primary outcome blinded to group allocation, and the remaining analyses were performed blinded by the first author.

Intervention

Both interventions have been described in detail in the published trial protocol following recommended guidelines.[27 31–33] The interventions were delivered at a physiotherapy clinic near the patients' homes, and the project covered all patient treatment expenses. All patients received education in scapular correction and joint protection adapted from the Danish Rheumatism Association.[34] Acceptable symptoms (<5/10 on a numerical pain rating scale) were allowed.[35] Patients filled out a printed exercise logbook with information about pain intensities, load,

Br J Sports Med: first published as 10.1136/bjsports-2021-105223 on 1 June 2022. Downloaded from http://bjsm.bmj.com/ on July 21, 2022 by guest. Protected by copyright.

progressions, repetitions, sets and adverse events at each session. Patients were encouraged to limit concomitant treatment (ie, manual therapy and steroid injection), of the shoulder and if necessary, to receive only as few treatments as possible and report it on the weekly questionnaires.

High-load shoulder strengthening exercise (HEAVY, intervention)

All patients randomised to HEAVY were individually supervised twice a week and encouraged to self-train once a week at home. We used five exercises for scapular and rotator cuff muscles[18 3619]using custom-made adjustable 3D-printed dumbbells (0–1000 g) and regular dumbbells (2–15 kg): Side-lying external rotation in neutral, prone horizontal abduction, prone external rotation at 90° shoulder abduction, supine scapular protraction and seated scaption. The warm-up consisted of 5 min of unloaded exercises. At the first session, the physiotherapist conducted a 5-repetition maximum (RM) test to estimate 10 RM (Brzycki's formula[37]); high-load was individually adjusted to a similar relative load for every patient and did not necessarily mean the application of a high external load in kg. The first three weeks consisted of familiarisation (3 sets of 10, week 1 at 50% of 10 RM, week 2 at 70% of 10 RM, week 3 at 90% of 10 RM). The following six weeks (weeks 4–9) included 3 sets of 10 RM. From weeks 10 to 15, the training included 4 sets of 8 RM.[38 39] A tapering period was applied in week 16 to allow for the anabolic response before follow-up testing.

Standard care (LIGHT, comparator)

The LIGHT programme was designed to mimic standard care in Denmark, primarily consisting of self-training exercises performed three times weekly. Patients received an individual introduction to exercises and supervision at weeks 5 and 11, where new exercises were introduced. The programme included nine shoulder exercises[18–20]: phase 1 (isometric), posture correction; phase 2 (isometric), shoulder abduction, shoulder internal and external rotation with 90° flexion at the elbow joint against a wall, and standing weight-bearing in the shoulders against a table; and phase 3 (dynamic with a yellow Theraband), shoulder abduction, shoulder internal and external rotation at 90° flexion at the elbow joint and four-point kneeling with single-arm raising.

Outcomes

Primary outcome measure

The primary outcome was self-reported shoulder function measured using the Western Ontario Shoulder Instability Index (WOSI) developed for patients with shoulder instability.[40] The questionnaire has 21 questions, each marked on a 0–100 scale (0=no shoulder limitations), range of 0–2100 points.[40] The WOSI subdomains are physical symptoms (10 questions), sports/recreation/work (four questions), lifestyle (four questions) and emotion (three questions), and the questionnaire is responsive, valid, sensitive to change, and has a high test–retest reliability.[41] The minimal important change was previously defined as 10.4%[40] and 14%,[42] corresponding to 218.4 and 294 points on the WOSI total score. A Danish-validated digital version was used.[43]

Secondary outcome measures

Secondary self-reported outcome measures were: the WOSI subdomains; shoulder pain worst, least and the average for the past week (scale 0–10)[44]; discomfort due to shoulder symptoms other than pain (instability, subluxation, laxity) (scale 0–10)[45]; Patient-Specific Functional Scale (scale 0–10)[46]; Checklist Individual Strength, the subscale of fatigue (scale 8–56)[47]; the COOP/WONCA questionnaire (scale 6–30)[48 49]; Tampa Scale of Kinesiophobia-11 (scale 11–44)[50]; European Quality of life-5 Dimensions-5-Level Scale (scale <0–1)[51 52]; EQ-Visual Analogue Scale (scale 0–100)[52 53]; Global Perceived Effect (GPE) on each of the WOSI subdomains (7-point scales, range: 'worse, an important worsening' to 'better, an important improvement').[54 55]

Secondary objective outcome measures were: isometric shoulder torque strength (Nm/kg) in scaption, internal rotation and external rotation using a handheld dynamometer (IsoForce Dynamometer EVO2; Medical Device Solution AG)[56 57]; Active and passive shoulder range of motion in internal and external rotation in 90° shoulder abduction[56 58] and proprioception in low-range and midrange shoulder flexion angles[59 60] assessed using a digital goniometer (Halo, Halo Medical Devices, Subiaco, Australia); shoulder laxity, hypermobility and instability assessed using the anterior and posterior load and shift[61] (positive: 2 or 3, glenoid head farther than the glenoid), sulcus sign[61] (positive <1 cm), Gagey[61] (positive >105°), apprehension[61] (positive: pain/apprehension), relocation[61] (positive: reduction of pain/apprehension), release[61] (positive: reappearing of pain/apprehension), Rotés Qúerol[30] (positive >90°) and shoulder rotation (positive: total passive range of motion above 180°) and flexion (positive: the whole humerus rested on table) tests.[62]

Furthermore, patients were asked about their use of painkillers, concomitant treatment and adverse events. We did not make any changes to the outcomes after the trial commenced. The GPE was measured at postintervention only, adverse events were measured throughout the intervention period and the remaining outcome measures were assessed at baseline and postintervention.

Sample size

We powered the trial to detect a between-group difference of at least 252 points (12%) based on previously reported minimal important change in the absence of patient-derived minimal important difference (MID) on the WOSI total score,[40 42] with a 350 points SD (based on group differences from previous RCTs).[18 26] With a two-sided significance level of 0.05% and 90% power, a sample size of 42 per group was required to detect a statistically significant difference. We decided to enrol 50 patients per group (expected dropout rate 16%).[18 20]

Statistical methods

A statistical analysis plan (https://osf.io/afgn2/) and blinded interpretation (https://osf.io/muztx/) were publicly available before any analysis commenced. The baseline characteristics were presented using descriptive analyses as mean (SD), median (IQR) or proportion (n (%)). Continuous data were checked for normality using the Shapiro-Wilk test and visual inspection of histogram and quantile–quantile plot. The ITT analyses included all randomised patients. We used a multivariable linear regression model to assess the between-group difference at 16 weeks with the primary outcome (WOSI total) as the dependent variable, and treatment group as the main effect, after adjusting for WOSI baseline score, age, sex and clustering around clinic (using cluster-robust standard errors). For continuous secondary outcomes, similar models were used. Multivariable logistic regressions were used for binary outcomes to estimate between-group odds ratio (OR) postintervention, with outcomes (clinical shoulder tests and GPE) as dependent variables and treatment

Br J Sports Med: first published as 10.1136/bjsports-2021-105223 on 1 June 2022. Downloaded from http://bjsm.bmj.com/ on July 21, 2022 by guest. Protected by copyright.

group as the main effect, adjusted with the baseline score of the outcomes of interest and the same other variables. The assumptions underlying the regression models, including normality, homogeneity of variance of residuals and linearity for quantitative predictors were met. Since the secondary outcomes were supportive, we did not adjust for multiple testing. For adverse events, self-reported pain medication use and other concomitant treatments received, the crude difference between risks and medians were calculated with 95% confidence interval (CI) based on the 'as observed' data while still respecting the original group allocation. For adverse events, the adjusted (age, sex, clustering around clinic) risk difference was estimated using margins after fitting a logistic regression model. Multiple imputation was used for missing data at follow-up for withdrawals with age, sex, group allocation (masked) and WOSI baseline values as predictors. For sensitivity purposes, we used baseline values carried forward.

Per-protocol analyses were applied using the same methods. The per-protocol population for both groups was defined as those attending at least two-thirds (67%) of the 48 planned exercise sessions, completing the intervention, and not receiving steroid injections or surgery. We performed a post hoc analysis of the number of successful (above 252 points) patients in HEAVY/LIGHT and calculated the numbers needed to treat (NNT) as the inverse of risk differences, adjusted for sex, age and clustering around clinic (fitting generalised linear models for the binomial family). An alpha level of 0.05 (two-sided) was considered statistically significant. Stata V.16 was used for the statistical analyses.

Public and patient involvement

Patients (n=12) from our feasibility study were involved in the trial design by providing feedback on the outcome measures and exercise programme, as described previously.[26] No members of the public or patients were involved in the conduct or interpretation of this trial.

Deviations from the registered trial protocol

We made no deviations from our published protocol.[27]

RESULTS

Recruitment ran from March 2019, and the final 16-week follow-ups were completed in February 2021. Figure 1 shows the flow of patients through the trial. Of the 100 randomly assigned patients with HSD (none with hypermobile Ehlers-Danlos Syndrome), 93 patients (93%) were followed up postintervention.

Patients were mainly women (79%), had a mean age of 37.8 years, with a mean Beighton score of 5.8 (table 1, online supplemental file 1). A total of 67 patients (HEAVY 34, LIGHT 33)




Figure 1 CONSORT flow diagram. ITT, intention-to-treat.

Br J Sports Med: first published as 10.1136/bjsports-2021-105223 on 1 June 2022. Downloaded from http://bjsm.bmj.com/ on July 21, 2022 by guest. Protected by copyright.

Table 1 Baseline characteristics for the intervention (HEAVY) and comparator (LIGHT) in patients with hypermobility spectrum disorder and shoulder symptoms

Variables	LIGHT, n=50	HEAVY, n=50
Sex (female), n (%)	39 (78)	40 (80)
Age (years)	37.0 (12.0)	38.6 (13.6)
Weight (kg)	81.6 (16.0)	79.0 (18.5)
Height (cm)	172.4 (9.2)	171.4 (8.9)
Hypermobility spectrum disorder		
Beighton score (scale 0–9)	5.8 (1.8)	5.8 (1.6)
5PQ (scale 0–5)	3.1 (1.2)	2.9 (1.1)
Generalised HSD, n (%)	40 (80)	47 (94)
Historical HSD, n (%)	10 (20)	3 (6)
Dominant writing hand (right), n (%)	48 (96)	43 (86)
Symptomatic shoulder (right), n (%)	30 (60)	27 (54)
Symptom duration (median months)	36 (11.8, 87)	43 (14.3, 120)
Previous shoulder dislocation (yes), n (%)	8 (16)	10 (20)
Feeling shoulder is loose (yes), n (%)	26 (52)	22 (44)
Primary outcome measure		
WOSI total (scale 0–2100)	1071.5 (379.8)	1042.1 (351.9)

Continuous data are presented as mean (SD) or median (IQR), and categorical variables are presented as proportion n (%).
HSD, hypermobility spectrum disorder; 5PQ, 5-part Questionnaire; WOSI, Western Ontario Shoulder Instability Index.

adhered to the interventions and constituted the per-protocol population. The reason for non-adherence was completing less than 32 exercise sessions (n=33); two patients from LIGHT had received steroid injections during the intervention.

Primary outcome

In the ITT analysis, HEAVY led to a greater improvement in shoulder function than LIGHT postintervention (WOSI total, adjusted mean difference, −174.5; 95% CI −341.4 to −7.7, 8.3%) (table 2). The adjusted mean difference was below the predefined MID. The per-protocol analysis demonstrated an even larger benefit favouring HEAVY (WOSI total, adjusted mean difference −250.7; 95% CI −323.4 to −178.0, 12%). The sensitivity analyses supported these findings (online supplemental file 3). The proportion of patients with a clinically relevant outcome favoured HEAVY (ITT 68% vs 54%), NNT 7 (95% CI 4 to 620), adjusted for age, sex and clustering around clinic; per-protocol 85% versus 55%, NNT 3 (95% CI 2 to 7), adjusted for age, sex and clustering around clinic.

Secondary outcomes

The secondary outcomes favoured HEAVY, but most were non-significant and with large CIs (table 2, online supplemental files 3 and 4). Postintervention, patients in HEAVY were less likely to have a positive shoulder rotation test (OR 0.32, 95% CI 0.13 to 0.80), and higher odds of rating an important improvement for 'physical symptoms' in GPE (OR 2.37, 95% CI 1.07 to 5.24). There were no serious adverse events, and HEAVY was associated with significantly more transient muscle soreness and headaches (table 3, per-protocol in online supplemental file 5). Two patients from HEAVY dropped out due to adverse events (table 3). There were no differences between the use of painkillers and concomitant treatment between the groups at baseline and post-intervention (online supplemental file 2).

DISCUSSION

HEAVY led to an 8.3% greater improvement in self-reported shoulder function than LIGHT at 16-week follow-up. Most secondary outcomes were inconclusive due to large CIs, but patients in HEAVY were less likely to have a positive shoulder rotation >180° and more likely to rate an important improvement in 'physical symptoms'. There were no serious adverse events, but more patients undergoing HEAVY experienced transient muscle soreness and headaches.

Our findings align with the between-group difference in WOSI (11.1% at 12 weeks) in a trial on multidirectional instability favouring a strengthening programme progressing in load and functional range of motion compared with strengthening primarily in 0 degrees of elevation.[18] Furthermore, our results support that exercise is a relevant and important treatment option for shoulder conditions.[63 64]

A priori, we defined the MID as a between-group difference of at least 12% (252 points). The mean between-group difference postintervention (8.3%, 174.5 WOSI total score) was statistically significant but below the MID, while the per-protocol analysis reached the MID (11.9%). When interpreting the results, it is important to acknowledge that the available MID thresholds are based on within-group changes, while the MID should be applied to changes in the number of individual patients, and not only group changes.[65 66] Although the post hoc analysis supported that 14% more patients in HEAVY reached improvements above 12%, at least 20% of additional improvements on pain and disability have been suggested as the cut point to consider that the effect of physiotherapy is worthwhile.[67] Therefore, the clinical relevance of the between-group difference remains unclear.[68] However, our finding adds to the debate regarding the relevance of prescribing additional doses of shoulder strengthening as a treatment for shoulder conditions, suggesting that progressive high-load strengthening may be relevant for the current population with HSD and shoulder symptoms.[69 70]

The rationale for using HEAVY was to impact the muscle cross-sectional areas and the voluntary activation of the available muscle mass to pose active joint stability to compensate for the lack of passive stability in hypermobile shoulders.[27] However, the mechanisms behind the effect of HEAVY are complex and also include psychosocial aspects and contextual effects.[71] Our findings, although non-significant, regarding the between-group difference in muscle strength in favour of HEAVY (scaption 10.4%, external rotation 12%) and the trend in less positive clinical tests (an indirect measure of muscle-tendon stiffness) may explain some of the effect of HEAVY on self-reported shoulder function and decreased physical symptoms. However, considering that several studies on shoulder pain-related conditions have failed to show superiority of progressive high-load strengthening exercise could indicate that other factors than the physical response to load are important.[19 69 70] Other factors may include the different types of exercise used in HEAVY and LIGHT (eg, full range or not) and the benefits of supervised and individually graded exercise to restore the ability of daily activities. This may have resulted in higher confidence and self-efficacy related to better function and psychosocial measures, such as shoulder related mental well-being and quality of life, which are components covered in WOSI total.[72 73]

HEAVY led to more transient muscle soreness and headache, considered minor and acceptable adverse events.[74] Muscle soreness can be seen as an important response to high-load strengthening exercise that should not be a barrier to successful treatment outcomes.[75] Besides patient education and intensive

Br J Sports Med: first published as 10.1136/bjsports-2021-105223 on 1 June 2022. Downloaded from http://bjsm.bmj.com/ on July 21, 2022 by guest. Protected by copyright.

Table 2 Outcomes at 16-week follow-up for the intervention (HEAVY) and comparator (LIGHT) in patients with hypermobility spectrum disorder and shoulder complaints

	Total no. of assessments (LIGHT/HEAVY)*	Mean at 16 weeks in LIGHT (95% CI) n=50	Mean at 16 weeks in HEAVY (95% CI) n=50	Between-group difference at 16 weeks (crude) (95% CI)	Between-group difference at 16 weeks (adjusted)† (95% CI)
Primary outcome measure					
WOSI total (scale 0–2100)	96/97	802.6 (683.9 to 921.3)	606.9 (481.1 to 732.7)	**−195.7 (−367.7 to -23.7)**	**−174.5 (−341.4 to -7.7)**
Secondary self-reported outcomes					
WOSI physical symptoms (scale 0–1000)	96/97	346.5 (286.9 to 406.2)	279.0 (222.4 to 335.6)	−67.5 (−149.3 to 14.3)	−68.6 (−144.7 to 7.4)
WOSI sports/recreation/work (scale 0–400)	96/97	150.7 (121.6 to 179.9)	111.8 (82.4 to 141.2)	−38.9 (−79.4 to 1.6)	−30.7 (−70.6 to 9.2)
WOSI lifestyle (scale 0–400)	96/97	134.5 (108.3 to 160.8)	96.6 (70.1 to 123.0)	**−38.0 (−74.8 to -1.1)**	−31.2 (−63.1 to 0.8)
WOSI emotions (scale 0–300)	96/97	169.3 (147.9 to 190.8)	121.7 (98.8 to 144.6)	**−47.6 (−78.9 to -16.4)**	**−43.5 (−72.0 to -14.9)**
Shoulder pain last 7 days (scale 0–10)					
Lowest rating	95/97	1.3 (0.7 to 1.9)	1.1 (0.6 to 1.6)	−0.2 (−1.0 to 0.5)	−0.3 (−1.0 to 0.4)
Highest rating	95/97	4.0 (3.2 to 4.8)	2.8 (2.1 to 3.5)	**−1.2 (−2.2 to -0.1)**	−1.0 (−2.0 to 0.1)
Average rating	95/97	2.3 (1.6 to 2.9)	1.7 (1.1 to 2.3)	−0.6 (−1.4 to 0.3)	−0.5 (−1.5 to 0.5)
Discomfort due to shoulder symptoms other than pain last 7 days (scale 0–10)					
Lowest rating	95/97	1.3 (0.8 to 1.7)	1.1 (0.6 to 1.6)	−0.1 (−0.8 to 0.5)	−0.2 (−0.9 to 0.5)
Highest rating	95/97	3.0 (2.3 to 3.7)	2.2 (1.6 to 2.8)	−0.8 (−1.7 to 0.1)	−0.6 (−1.2 to 0.1)
Average rating	95/97	1.9 (1.4 to 2.5)	1.5 (1.0 to 2.1)	−0.4 (−1.1 to 0.3)	−0.2 (−0.9 to 0.4)
Patient-Specific Functional Scale (scale 0–10)	95/97	5.6 (4.8 to 6.3)	5.7 (5.0 to 6.5)	0.2 (−0.9 to 1.3)	0.2 (−1.0 to 1.4)
Checklist Individual Strength (scale 8–56)	95/97	32.5 (28.7 to 36.3)	29.8 (26.4 to 33.1)	−2.7 (−7.7 to 2.3)	−2.5 (−7.1 to 2.2)
COOP/WONCA (scale 6–30)	94/97	14.0 (12.7 to 15.3)	12.9 (11.6 to 14.1)	−1.2 (−3.0 to 0.6)	−0.5 (−2.2 to 1.2)
Tampa Scale of Kinesiophobia (scale 11–44)	94/97	22.2 (20.4 to 24.1)	20.5 (18.8 to 22.1)	−1.8 (−4.2 to 0.7)	−0.8 (−2.7 to 1.1)
EQ-5D-5L (scale <0–1)	94/97	0.76 (0.72 to 0.79)	0.80 (0.76 to 0.83)	0.04 (−0.01 to 0.09)	0.02 (−0.02 to 0.07)
EQ-VAS (scale 0–100)	94/97	69.6 (64.0 to 75.2)	75.3 (70.6 to 80.1)	5.7 (−1.5 to 13.0)	0.3 (−8.0 to 8.6)
Secondary objective outcomes					
Range of motion (°)					
Internal rotation passive	87/90	72.6 (67.3 to 78.0)	69.9 (64.7 to 75.2)	−2.70 (−10.6 to 5.2)	−0.6 (−11.3 to 10.2)
Internal rotation active	87/90	68.9 (64.1 to 73.7)	71.2 (66.8 to 75.7)	2.4 (−4.5 to 9.2)	4.0 (−4.2 to 12.2)
External rotation passive	87/90	105.3 (96.9 to 113.7)	107.6 (100.0 to 115.1)	2.2 (−9.8 to 14.3)	−0.5 (−16.4 to 15.4)
External rotation active	87/90	100.6 (93.2 to 108.1)	107.0 (100.5 to 113.6)	6.4 (−4.2 to 17.0)	3.4 (−10.8 to 17.5)
Isometric shoulder torque strength (Nm/kg)					
Scaption	87/90	0.48 (0.42 to 0.54)	0.52 (0.45 to 0.59)	0.04 (−0.05 to 0.14)	0.05 (−0.04 to 0.13)
Internal rotation	87/90	0.37 (0.32 to 0.42)	0.36 (0.30 to 0.41)	−0.01 (−0.09 to 0.06)	0.00 (−0.07 to 0.07)
External rotation	87/90	0.25 (0.22 to 0.28)	0.27 (.23 to 0.31)	0.02 (−0.03 to 0.07)	0.03 (−0.03 to 0.08)
Proprioception in flexion (error °)					
Low range	87/90	4.65 (3.71 to 5.60)	4.98 (3.85 to 6.11)	0.33 (−1.24 to 1.90)	0.65 (−1.60 to 2.90)
Mid-range	86/90	3.34 (2.65 to 4.04)	4.51 (3.47 to 5.54)	**1.17 (0.01 to 2.32)**	1.17 (−0.27. 2.60)
Shoulder instability and laxity tests (positive %)‡					
Shoulder flexion test, positive=yes	87/90	78 (64 to 91)	62 (47 to 76)	OR 0.46 (0.17 to 1.21)	OR 0.40 (0.09 to 1.75)
Shoulder rotation test, positive >180°	87/90	62 (47 to 76)	42 (28 to 56)	OR 0.44 (0.19 to 1.03)	**OR 0.32 (0.13 to 0.80)**
Apprehension test, positive=yes	87/90	70 (55 to 85)	62 (48 to 76)	OR 0.70 (0.29 to 1.65)	OR 0.59 (0.31 to 1.13)
Relocation test,§ positive=yes	87/90	55 (38 to 72)	44 (30 to 58)	OR 0.66 (0.28 to 1.56)	OR 0.59 (0.33 to 1.08)
Release test,§ positive=yes	87/90	50 (32 to 68)	37 (23 to 51)	OR 0.58 (0.24 to 1.39)	OR 0.58 (0.25 to 1.35)
Load and shift anterior, positive 2–3	87/90	68 (52 to 84)	62 (47 to 77)	OR 0.77 (0.31 to 1.90)	OR 0.56 (0.23 to 1.40)
Load and shift posterior, positive 2–3	87/90	28 (13 to 44)	18 (7 to 29)	OR 0.57 (0.20 to 1.61)	OR 0.63 (0.19 to 2.04)
Sulcus sign, positive >1 cm	87/90	84 (68 to 93)	85 (70 to 93)	OR 0.97 (0.28 to 3.34)	OR 1.05 (0.28 to 3.94)
Gagey, positive >105°	87/90	92 (85 to 100)	90 (78 to 100)	OR 0.73 (0.15 to 3.43)	OR 0.43 (0.14 to 1.37)
Rotés Queról, positive >90°	87/90	63 (48 to 77)	55 (41 to 69)	OR 0.73 (0.31 to 1.72)	OR 0.72 (0.20 to 2.66)
Global Perceived Effect‡¶					
(% rated important effect postintervention)					
Physical symptoms	45/47	44 (31 to 59)	64 (49 to 76)	OR 2.21 (0.96 to 5.09)	**OR 2.37 (1.07 to 5.24)**
Sports/recreation/work	45/47	38 (25 to 53)	51 (37 to 65)	OR 1.72 (0.75 to 3.94)	OR 1.82 (0.82 to 4.03)
Lifestyle	45/47	44 (31 to 59)	55 (41 to 69)	OR 1.55 (0.68 to 3.52)	OR 1.60 (0.65 to 3.96)
Emotions	45/47	40 (27 to 55)	51 (37 to 65)	OR 1.57 (0.69 to 3.58)	OR 1.57 (0.51 to 4.85)

Statistically significant results (p<0.05) are marked with bold.
*There were 100 possible assessments for each group (50 at baseline and 50 at 16 weeks follow-up), except for Global Perceived Effect which had 50 possible assessments for each group.
†The results are adjusted for baseline score, age, sex and the clustering around physiotherapy clinic.
‡Proportions of positive test in % (95% CI) and OR for between-group differences with group LIGHT as reference.
§Relocation and release tests were only performed on patients with a positive apprehension test.
¶No data imputation.
COOP/WONCA, Dartmouth Primary Care Cooperative Research Network/World Organization of National Colleges, Academies and Academic Associations of General Practitioners/Family Physicians; EQ-5D-5L, European Quality of life-5 Dimensions-5-Level; VAS, visual analogue scale; WOSI, Western Ontario Shoulder Instability Index.

Br J Sports Med: first published as 10.1136/bjsports-2021-105223 on 1 June 2022. Downloaded from http://bjsm.bmj.com/ on July 21, 2022 by guest. Protected by copyright.

Table 3 Adverse events (specific, serious or minor, and withdrawals due to adverse events), and crude difference between risks and medians were calculated with 95% CIs based on the 'as observed' data while still respecting the original group allocation, from baseline to 16-week follow-up for the intervention (HEAVY) versus comparator (LIGHT) in patients with hypermobility spectrum disorder and shoulder symptoms

Adverse events	LIGHT (n=46)	HEAVY (n=45)	Between-group risk difference or median difference with 95% CI (crude)*
Number of patients reporting serious adverse events†	0 (0)	0 (0)	0 (0 to 0)
Number of patients reporting minor adverse events (n (%))	24 (52)	29 (64)	12 (–8 to 32)
Index shoulder			
Muscle soreness	17 (37)	25 (56)	19 (–2 to 39)
Shoulder is locked	3 (4)	2 (4)	–2 (–11 to 7)
Subluxation	3 (7)	1 (2)	–4 (–12 to 4)
Dislocation	0 (0)	1 (2)	2 (–2 to 7)
Persistent worsening of symptoms	8 (17)	8 (18)	0 (–15 to 16)
Other sites than index shoulder			
Headache	9 (20)	18 (40)	**20 (2 to 39)**
'Other' minor events related to index shoulder or other sites	18 (39)	19 (42)	3 (–17 to 23)
Total number of adverse events			
Number of minor adverse events (median (95% CI)‡	1 (0 to 1.1)	2 (0.4 to 4.0)	1 (–0.6 to 2.6)
Index shoulder			
Muscle soreness	0 (0 to 1)	1 (0 to 2)	1 (–0.1 to 2.1)
Shoulder is locked	0 (0 to 0)	0 (0 to 0)	0 (0 to 0)
Subluxation	0 (0 to 0)	0 (0 to 0)	0 (0 to 0)
Dislocation	0 (0 to 0)	0 (0 to 0)	0 (0 to 0)
Persistent worsening of symptoms	0 (0 to 0)	0 (0 to 0)	0 (0 to 0)
Other sites than index shoulder			
Headache	0 (0 to 0)	0 (0 to 1)	0 (0 to 0)
'Other' minor events related to index shoulder or other sites	0 (0 to 1)	0 (0 to 1)	0 (0 to 0)
Number of dropouts due to adverse events (n, (%))	0 (0)	2 (4)§	4 (–2 to 10)

This table includes all adverse events that occurred during the 16-week study period, but which did not necessarily have a causal relationship with the treatment administered. Statistically significant results (p<0.05) are marked with bold.
*The adjusted (age, sex, clustering around clinic) risk difference using margins after fitting a logistic regression model did not change the estimates (online supplemental file 6).
†Serious adverse events were unexpected but covered death, life-threatening events, disability and permanent damage.
‡For each patient, each adverse event could count 0–16 times corresponding with 16 weeks intervention period.
§One dropout due to worsening of symptoms caused by lack of supervision during COVID-19 pandemic, and one patient had suffered from a hand fracture not related to the intervention (data not included in table 3).

supervision to manage potential symptom flares, the current trial did not employ manual therapy or other physiotherapy modalities to gain short-term relief (eg, from headaches) that could have increased exercise adherence.[64 76]

This trial has limitations. We developed LIGHT as an active comparator to mimic the average exercise-based standard treatment offered across physiotherapy clinics in Danish primary care. Since there is a considerable variation in treatments among clinicians, we could potentially have offered the patients a better or worse treatment than they would have received usually. However, LIGHT is considered a better approach than wait-and-see or no treatment for this patient group.[63 77] We were unable to blind patients, and the nature of the intervention meant that we could not blind the treatment providers, but we presented both interventions as having the potential to be effective. It is, however, possible that the treating physiotherapists could have favoured one intervention over the other (care provider bias). The two interventions in this trial are of varying complexity in training and delivery, with the number of supervised sessions being one of the major differences between interventions. Because HEAVY is a new exercise approach, it was deemed important to provide intensive supervision to manage potential adverse events and adequate load progression. Although there is convincing evidence that supervised exercise and self-training are equally effective for shoulder conditions, thereby decreasing the risk of attention bias,[63] it is unknown whether this can be extended to patients with HSD as they may have decreased tissue stiffness and difficulties in performing strengthening exercise unsupervised, which may compromise patient safety. Furthermore, the generalisability to patients with hypermobile Ehlers-Danlos Syndrome, patients referred to secondary care (eg, specialised hypermobility units), and other international/cultural settings is unanswered. Many of the CIs were inconclusive, reflecting low precision of the trial estimates. We did not adjust for multiple testing since all secondary outcomes were declared supportive. However, we cannot rule out statistical significance by chance for the secondary outcomes. Furthermore, the validity of the trial results depends on the correct specification of the regression models as well as imputation model. The issue of unmeasured random confounding (and adjustment for few confounders) may be considered as a limitation of the trial. The measurement bias in the ITT estimates is a limitation but the WOSI baseline score for those patients who were and were not in the per-protocol population did not differ. Although relevant, it was not within the scope of this trial to evaluate the cost-effectiveness of the interventions. Still, it may be conducted later using the Danish national registries.

This trial had strengths. The pragmatic approach of this trial using broad eligibility criteria, a consecutive sampling strategy, standard care as the comparator, and patients recruited from primary care improve the generalisability of the findings. The pre-registration at ClinicalTrials.gov and publication of the a

Br J Sports Med: first published as 10.1136/bjsports-2021-105223 on 1 June 2022. Downloaded from http://bjsm.bmj.com/ on July 21, 2022 by guest. Protected by copyright.

priori trial protocol, statistical analysis plan, blinded interpretation of the findings, and thoroughly described exercise protocols based on established frameworks greatly improve the overall quality of the current study and the potential for implementation.

In conclusion, supervised, progressive, high-load strengthening exercise was statistically superior to less supervised and less progressive, low-load exercise and may be used as treatment in patients with HSD and shoulder symptoms in primary care to improve shoulder function. However, only eight percent of the secondary outcomes significantly supported the primary outcome. Clinicians should pay attention to and help alleviate minor transient symptoms following the treatment. Further studies are needed to confirm the clinical relevance, the long-term effectiveness and the underlying mechanisms of high-load strenghtening exercise.

Twitter Behnam Liaghat @behnam_liaghat, Søren T Skou @STSkou, Jens Søndergaard @JensSndergaard1, Karen Søgaard @KASogaard and Birgit Juul-Kristensen @birgit_juul

Acknowledgements We thank all the patients who agreed to be involved in this project. We also want to acknowledge Anne Marie Rosager for her role as the project manager, Professor Carsten Bogh Juhl and Professor Robin Christensen (Cochrane Musculoskeletal group) for statistical assistance during manuscript revisions, and the Odense Patient data Explorative Network, Odense University Hospital, Odense, Denmark, for data management support and access to REDCap. Lastly, we thank all the medical doctors and physiotherapists responsible for recruiting patients, physiotherapists who delivered the interventions, and the outcome assessors Iben Lings Brøndlund Hansen, Martin Petersen, Stefan Snedevind Jørgensen and Jon Ludvig Hansen who were responsible for baseline and 16-week follow-up testing.

Contributors BL and BJ-K conceived the study idea. All authors initiated the study design. BL, BJ-K, STS and JS helped with the implementation. BL, BJ-K and EB provided statistical expertise in the study design and planning of the primary and secondary statistical analyses. EB performed the blinded intention-to-treat analysis of the primary outcome. BL, BJ-K, STS and KS contributed to the design of the study intervention. BL was the grant holder and principal investigator and responsible for patient inclusion and data collection. BL trained the study personnel in testing procedures. BL drafted this paper, and all authors have been involved in drafting versions and critically revising it for important intellectual content and have read and approved the final version. BL is the guarantor of the study.

Funding This work was supported by the Region of Southern Denmark; Esbjerg municipality; The Danish Rheumatism Association; Fund for Research, Quality and Education in Physiotherapy Practice; and the University of Southern Denmark, all in Denmark. STS is currently funded by a programme grant from Region Zealand in Denmark (Exercise First) and two grants from the European Union's Horizon 2020 research and innovation programme, one from the European Research Council (MOBILIZE, grant agreement No 801790) and the other under grant agreement No 945377 (ESCAPE).

Competing interests STS reports personal fees from the Journal of Orthopaedic & Sports Physical Therapy, grants from The Lundbeck Foundation, and personal fees from Munksgaard, outside the submitted work, and being a co-founder of Good Life with osteoArthritis in Denmark (GLA:D®). GLA:D is a non-profit initiative hosted at the University of Southern Denmark aimed at implementing clinical guidelines for osteoarthritis in clinical practice. JS reports receiving grants from Astra-Zeneca, outside the submitted work.

Patient and public involvement Patients and/or the public were involved in the design, or conduct, or reporting, or dissemination plans of this research. Refer to the Methods section for further details.

Patient consent for publication Not applicable.

Ethics approval This trial involves human participants and was approved by The Regional Committees on Health Research Ethics for Southern Denmark (31 May 2017, S-20170066) Participants gave informed consent to participate in the trial before taking part.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement Data are available upon reasonable request.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

ORCID iDs
Behnam Liaghat http://orcid.org/0000-0002-3050-0028
Søren T Skou http://orcid.org/0000-0003-4336-7059
Jens Søndergaard http://orcid.org/0000-0002-1629-1864
Eleanor Boyle http://orcid.org/0000-0002-9012-9128
Karen Søgaard http://orcid.org/0000-0003-3968-6364
Birgit Juul-Kristensen http://orcid.org/0000-0002-4973-8415

REFERENCES

1 Remvig L, Jensen DV, Ward RC. Epidemiology of general joint hypermobility and basis for the proposed criteria for benign joint hypermobility syndrome: review of the literature. *J Rheumatol* 2007;34:804–9.
2 Juul-Kristensen B, Østengaard L, Hansen S, *et al*. Generalised joint hypermobility and shoulder joint hypermobility, - risk of upper body musculoskeletal symptoms and reduced quality of life in the general population. *BMC Musculoskelet Disord* 2017;18:226.
3 Johnson SM, Robinson CM. Shoulder instability in patients with joint hyperlaxity. *J Bone Joint Surg Am* 2010;92:1545–57.
4 Mulvey MR, Macfarlane GJ, Beasley M, *et al*. Modest association of joint hypermobility with disabling and limiting musculoskeletal pain: results from a large-scale General population-based survey. *Arthritis Care Res* 2013;65:1325–33.
5 Scheper MC, Juul-Kristensen B, Rombaut L, *et al*. Disability in adolescents and adults diagnosed with Hypermobility-Related disorders: a meta-analysis. *Arch Phys Med Rehabil* 2016;97:2174–87.
6 Smith TO, Easton V, Bacon H, *et al*. The relationship between benign joint hypermobility syndrome and psychological distress: a systematic review and meta-analysis. *Rheumatology* 2014;53:114–22.
7 Liaghat B, Pedersen JR, Young JJ, *et al*. Joint hypermobility in athletes is associated with shoulder injuries: a systematic review and meta-analysis. *BMC Musculoskelet Disord* 2021;22:389.
8 Castori M, Tinkle B, Levy H, *et al*. A framework for the classification of joint hypermobility and related conditions. *Am J Med Genet C Semin Med Genet* 2017;175:148–57.
9 Johannessen EC, Reiten HS, Løvaas H, *et al*. Shoulder function, pain and health related quality of life in adults with joint hypermobility syndrome/Ehlers-Danlos syndrome-hypermobility type. *Disabil Rehabil* 2016;38:1382–90.
10 Rombaut L, Malfait F, Cools A, *et al*. Musculoskeletal complaints, physical activity and health-related quality of life among patients with the Ehlers-Danlos syndrome hypermobility type. *Disabil Rehabil* 2010;32:1339–45.
11 Palmer S, Cramp F, Lewis R, *et al*. Development and initial validation of the Bristol impact of hypermobility questionnaire. *Physiotherapy* 2017;103:186–92.
12 Spanhove V, Calders P, Berckmans K, *et al*. Electromyographic Muscle Activity and Three-Dimensional Scapular Kinematics in Patients With Multidirectional Shoulder Instability: A Study in the Hypermobile Type of the Ehlers-Danlos Syndrome and the Hypermobility Spectrum Disorders. *Arthritis Care Res* 2022;74:833–40.
13 Kjær BH, de Wandele I, Spanhove V, *et al*. Subacromial space outlet in female patients with multidirectional instability based on hypermobile Ehlers-Danlos syndrome and hypermobility spectrum disorder measured by ultrasound. *J Shoulder Elbow Surg* 2020;29:600–8.
14 Smith TO, Bacon H, Jerman E, *et al*. Physiotherapy and occupational therapy interventions for people with benign joint hypermobility syndrome: a systematic review of clinical trials. *Disabil Rehabil* 2014;36:797–803.
15 Palmer S, Bailey S, Barker L, *et al*. The effectiveness of therapeutic exercise for joint hypermobility syndrome: a systematic review. *Physiotherapy* 2014;100:220–7.
16 Warby SA, Pizzari T, Ford JJ, *et al*. The effect of exercise-based management for multidirectional instability of the glenohumeral joint: a systematic review. *J Shoulder Elbow Surg* 2014;23:128–42.
17 Engelbert RHH, Juul-Kristensen B, Pacey V, *et al*. The evidence-based rationale for physical therapy treatment of children, adolescents, and adults diagnosed with joint hypermobility syndrome/hypermobile Ehlers Danlos syndrome. *Am J Med Genet C Semin Med Genet* 2017;175:158–67.
18 Warby SA, Ford JJ, Hahne AJ, *et al*. Comparison of 2 exercise rehabilitation programs for multidirectional instability of the Glenohumeral joint: a randomized controlled trial. *Am J Sports Med* 2018;46:87–97.
19 Ingwersen KG, Jensen SL, Sørensen L, *et al*. Three months of progressive High-Load versus traditional Low-Load strength training among patients with rotator cuff tendinopathy: primary results from the double-blind randomized controlled RoCTEx trial. *Orthop J Sports Med* 2017;5:2325967117723292.

Br J Sports Med: first published as 10.1136/bjsports-2021-105223 on 1 June 2022. Downloaded from http://bjsm.bmj.com/ on July 21, 2022 by guest. Protected by copyright.

20 Eshoj HR, Rasmussen S, Frich LH, *et al*. Neuromuscular exercises improve shoulder function more than standard care exercises in patients with a traumatic anterior shoulder dislocation: a randomized controlled trial. *Orthop J Sports Med* 2020;8:2325967119896102.
21 Laudner KG, Metz B, Thomas DQ. Anterior glenohumeral laxity and stiffness after a shoulder-strengthening program in collegiate cheerleaders. *J Athl Train* 2013;48:25–30.
22 Couppé C, Kongsgaard M, Aagaard P, *et al*. Habitual loading results in tendon hypertrophy and increased stiffness of the human Patellar tendon. *J Appl Physiol* 2008;105:805–10.
23 Alsiri N, Al-Obaidi S, Asbeutah A, *et al*. The impact of hypermobility spectrum disorders on musculoskeletal tissue stiffness: an exploration using strain elastography. *Clin Rheumatol* 2019;38:85–95.
24 Coussens M, Lapauw B, Banica T, *et al*. Muscle strength, muscle mass and physical impairment in women with hypermobile Ehlers-Danlos syndrome and hypermobility spectrum disorder. *J Musculoskelet Neuronal Interact* 2022;22:5–14.
25 The Danish Rheumatism Association. Treatment of hypermobility - prevention of pain and injuries, 2015. Available: https://www.gigtforeningen.dk/viden-om-gigt/diagnoser/hypermobilitet/behandling-af-hypermobilitet/2015https://www.gigtforeningen.dk/viden-om-gigt/diagnoser/hypermobilitet/behandling-af-hypermobilitet/
26 Liaghat B, Skou ST, Jørgensen U, *et al*. Heavy shoulder strengthening exercise in people with hypermobility spectrum disorder (HSD) and long-lasting shoulder symptoms: a feasibility study. *Pilot Feasibility Stud* 2020;6:97.
27 Liaghat B, Skou ST, Søndergaard J, *et al*. A randomised controlled trial of heavy shoulder strengthening exercise in patients with hypermobility spectrum disorder or hypermobile Ehlers-Danlos syndrome and long-lasting shoulder complaints: study protocol for the Shoulder-MOBILEX study. *Trials* 2020;21:992.
28 Malfait F, Francomano C, Byers P, *et al*. The 2017 International classification of the Ehlers-Danlos syndromes. *Am J Med Genet C Semin Med Genet* 2017;175:8–26.
29 Hakim AJ, Grahame R. A simple questionnaire to detect hypermobility: an adjunct to the assessment of patients with diffuse musculoskeletal pain. *Int J Clin Pract* 2003;57:163–6.
30 Juul-Kristensen B, Røgind H, Jensen DV, *et al*. Inter-Examiner reproducibility of tests and criteria for generalized joint hypermobility and benign joint hypermobility syndrome. *Rheumatology* 2007;46:1835–41.
31 Slade SC, Dionne CE, Underwood M, *et al*. Consensus on exercise reporting template (CERT): modified Delphi study. *Phys Ther* 2016;96:1514–24.
32 Hoffmann TC, Glasziou PP, Boutron I, *et al*. Better reporting of interventions: template for intervention description and replication (TIDieR) checklist and guide. *BMJ* 2014;348:g1687.
33 Toigo M, Boutellier U. New fundamental resistance exercise determinants of molecular and cellular muscle adaptations. *Eur J Appl Physiol* 2006;97:643–63.
34 Gigtforeningen. Behandling af hypermobilitet - forebyggelse af smerter og skader Gigtforeningen.dk: Gigtforeningen, 2015. Available: https://www.gigtforeningen.dk/viden-om-gigt/diagnoser/hypermobilitet/behandling-af-hypermobilitet/2021
35 Silbernagel KG, Thomeé R, Eriksson BI, *et al*. Continued sports activity, using a pain-monitoring model, during rehabilitation in patients with Achilles tendinopathy: a randomized controlled study. *Am J Sports Med* 2007;35:897–906.
36 Watson L, Balster S, Lenssen R, *et al*. The effects of a conservative rehabilitation program for multidirectional instability of the shoulder. *J Shoulder Elbow Surg* 2018;27:104–11.
37 Brzycki M. Strength Testing—Predicting a One-Rep max from Reps-to-Fatigue. *J Phys Educ Recreat Dance* 1993;64:88–90.
38 Møller MB, Kjær M, Svensson RB, *et al*. Functional adaptation of tendon and skeletal muscle to resistance training in three patients with genetically verified classic Ehlers Danlos syndrome. *Muscles Ligaments Tendons J* 2014;4:315–23.
39 Medicine ACoS. *ACSM's guidelines for exercise testing and prescription*. Lippincott Williams & Wilkins, 2013.
40 Kirkley A, Werstine R, Ratjek A, *et al*. Prospective randomized clinical trial comparing the effectiveness of immediate arthroscopic stabilization versus immobilization and rehabilitation in first traumatic anterior dislocations of the shoulder: long-term evaluation. *Arthroscopy* 2005;21:55–63.
41 Salomonsson B, Ahlström S, Dalén N, *et al*. The Western Ontario shoulder instability index (WOSI): validity, reliability, and responsiveness retested with a Swedish translation. *Acta Orthop* 2009;80:233–8.
42 van der Linde JA, van Kampen DA, van Beers LWAH, *et al*. The responsiveness and minimal important change of the Western Ontario shoulder instability index and Oxford shoulder instability score. *J Orthop Sports Phys Ther* 2017;47:402–10.
43 Eshoj H, Bak K, Blønd L, *et al*. Translation, adaptation and measurement properties of an electronic version of the Danish Western Ontario shoulder instability index (WOSI). *BMJ Open* 2017;7:e014053.
44 Breivik H, Borchgrevink PC, Allen SM, *et al*. Assessment of pain. *Br J Anaesth* 2008;101:17–24.
45 Liaghat B, Skou ST, Sondergaard J, *et al*. Clinical characteristics of 100 patients with hypermobility spectrum disorders and shoulder complaints with or without mechanical symptoms: a cross-sectional study. *Arch Phys Med Rehabil* 2022. doi:10.1016/j.apmr.2021.12.021. [Epub ahead of print: 21 Jan 2022].
46 Donnelly C, Carswell A. Individualized outcome measures: a review of the literature. *Can J Occup Ther* 2002;69:84–94.
47 Voermans NC, Knoop H. Both pain and fatigue are important possible determinants of disability in patients with the Ehlers-Danlos syndrome hypermobility type. *Disabil Rehabil* 2011;33:706–7.
48 Bentsen BG, Natvig B, Winnem M. Questions you didn't ask? COOP/WONCA Charts in clinical work and research. World Organization of Colleges, Academies and Academic Associations of General Practitioners/Family Physicists. *Fam Pract* 1999;16:190–5.
49 Kinnersley P, Peters T, Stott N. Measuring functional health status in primary care using the COOP-WONCA charts: acceptability, range of scores, construct validity, reliability and sensitivity to change. *Br J Gen Pract* 1994;44:545–9.
50 Mintken PE, Cleland JA, Whitman JM, *et al*. Psychometric properties of the Fear-Avoidance beliefs questionnaire and Tampa scale of Kinesiophobia in patients with shoulder pain. *Arch Phys Med Rehabil* 2010;91:1128–36.
51 Janssen MF, Pickard AS, Golicki D, *et al*. Measurement properties of the EQ-5D-5L compared to the EQ-5D-3L across eight patient groups: a multi-country study. *Qual Life Res* 2013;22:1717–27.
52 Hinz A, Kohlmann T, Stöbel-Richter Y, *et al*. The quality of life questionnaire EQ-5D-5L: psychometric properties and normative values for the general German population. *Qual Life Res* 2014;23:443–7.
53 Skare Øystein, Liavaag S, Reikerås O, *et al*. Evaluation of Oxford instability shoulder score, Western Ontario shoulder instability index and Euroqol in patients with slap (superior labral anterior posterior) lesions or recurrent anterior dislocations of the shoulder. *BMC Res Notes* 2013;6:273.
54 Kamper SJ, Ostelo RWJG, Knol DL, *et al*. Global perceived effect scales provided reliable assessments of health transition in people with musculoskeletal disorders, but ratings are strongly influenced by current status. *J Clin Epidemiol* 2010;63:760–6.
55 Ingelsrud LH, Terwee CB, Terluin B, *et al*. Meaningful change scores in the knee injury and osteoarthritis outcome score in patients undergoing anterior cruciate ligament reconstruction. *Am J Sports Med* 2018;46:1120–8.
56 Ingwersen KG, Christensen R, Sørensen L, *et al*. Progressive high-load strength training compared with general low-load exercises in patients with rotator cuff tendinopathy: study protocol for a randomised controlled trial. *Trials* 2015;16:27.
57 Kjær BH, Magnusson SP, Warming S, *et al*. Progressive early passive and active exercise therapy after surgical rotator cuff repair - study protocol for a randomized controlled trial (the CUT-N-MOVE trial). *Trials* 2018;19:470.
58 Clarsen B, Bahr R, Andersson SH, *et al*. Reduced glenohumeral rotation, external rotation weakness and scapular dyskinesis are risk factors for shoulder injuries among elite male handball players: a prospective cohort study. *Br J Sports Med* 2014;48:1327–33.
59 Vafadar AK, Côté JN, Archambault PS. Interrater and intrarater reliability and validity of 3 measurement methods for Shoulder-Position sense. *J Sport Rehabil* 2016;25:2014-0309.
60 Eshoj H, Rasmussen S, Frich LH, *et al*. A neuromuscular exercise programme versus standard care for patients with traumatic anterior shoulder instability: study protocol for a randomised controlled trial (the SINEX study). *Trials* 2017;18:90.
61 Eshoj H, Ingwersen KG, Larsen CM, *et al*. Intertester reliability of clinical shoulder instability and laxity tests in subjects with and without self-reported shoulder problems. *BMJ Open* 2018;8:e018472.
62 Nicholson LL, Chan C. The upper limb hypermobility assessment tool: a novel validated measure of adult joint mobility. *Musculoskelet Sci Pract* 2018;35:38–45.
63 Liaghat B, Ussing A, Petersen BH, *et al*. Supervised training compared with no training or Self-training in patients with subacromial pain syndrome: a systematic review and meta-analysis. *Arch Phys Med Rehabil* 2021;102:2428–41.
64 Pieters L, Lewis J, Kuppens K, *et al*. An update of systematic reviews examining the effectiveness of conservative physical therapy interventions for subacromial shoulder pain. *J Orthop Sports Phys Ther* 2020;50:131–41.
65 Katz NP, Paillard FC, Ekman E. Determining the clinical importance of treatment benefits for interventions for painful orthopedic conditions. *J Orthop Surg Res* 2015;10:24.
66 Roos EM. 3 steps to improve reporting and interpretation of patient-reported outcome scores in orthopedic studies. *Acta Orthop* 2018;89:1–2.
67 Christiansen DH, de Vos Andersen N-B, Poulsen PH, *et al*. The smallest worthwhile effect of primary care physiotherapy did not differ across musculoskeletal pain sites. *J Clin Epidemiol* 2018;101:44–52.
68 Ferreira M. Research note: the smallest worthwhile effect of a health intervention. *J Physiother* 2018;64:272–4.
69 Clausen MB, Hölmich P, Rathleff M, *et al*. Effectiveness of adding a large dose of shoulder strengthening to current Nonoperative care for subacromial impingement: a pragmatic, double-blind randomized controlled trial (SExSI trial). *Am J Sports Med* 2021;49:3040–9.
70 Hopewell S, Keene DJ, Marian IR, *et al*. Progressive exercise compared with best practice advice, with or without corticosteroid injection, for the treatment of patients with rotator cuff disorders (GRASP): a multicentre, pragmatic, 2 × 2 factorial, randomised controlled trial. *Lancet* 2021;398:416–28.
71 Zou K, Wong J, Abdullah N, *et al*. Examination of overall treatment effect and the proportion attributable to contextual effect in osteoarthritis: meta-analysis of randomised controlled trials. *Ann Rheum Dis* 2016;75:1964–70.

Br J Sports Med: first published as 10.1136/bjsports-2021-105223 on 1 June 2022. Downloaded from http://bjsm.bmj.com/ on July 21, 2022 by guest. Protected by copyright.

72 Kirkley A, Griffin S, McLintock H, *et al*. The development and evaluation of a disease-specific quality of life measurement tool for shoulder instability. The Western Ontario shoulder instability index (WOSI). *Am J Sports Med* 1998;26:764–72.
73 Chester R, Khondoker M, Shepstone L, *et al*. Self-Efficacy and risk of persistent shoulder pain: results of a classification and regression tree (CART) analysis. *Br J Sports Med* 2019;53:825–34.
74 Niemeijer A, Lund H, Stafne SN, *et al*. Adverse events of exercise therapy in randomised controlled trials: a systematic review and meta-analysis. *Br J Sports Med* 2020;54:1073.
75 Smith BE, Hendrick P, Smith TO, *et al*. Should exercises be painful in the management of chronic musculoskeletal pain? A systematic review and meta-analysis. *Br J Sports Med* 2017;51:1679.
76 Dong W, Goost H, Lin X-B, *et al*. Treatments for shoulder impingement syndrome: a PRISMA systematic review and network meta-analysis. *Medicine* 2015;94:e510.
77 Malliaras P, Johnston R, Street G, *et al*. The efficacy of higher versus lower dose exercise in rotator cuff tendinopathy: a systematic review of randomized controlled trials. *Arch Phys Med Rehabil* 2020;101:1822–34.

Br J Sports Med: first published as 10.1136/bjsports-2021-105223 on 1 June 2022. Downloaded from http://bjsm.bmj.com/ on July 21, 2022 by guest. Protected by copyright.

Supplementary file 1. Table. Baseline characteristics for HEAVY and LIGHT.

Variables	LIGHT n=50	HEAVY n=50
Physical activity (IPAQ short version), n (%)		
Low	28 (56)	25 (50)
Moderate	16 (32)	20 (40)
High	6 (12)	5 (10)
Education (%)		
Academic education	24 (48)	26 (52)
Vocational education	12 (24)	16 (32)
Unskilled labour/no education	14 (28)	8 (16)
Employment status (%)		
Full-time	26 (52)	28 (56)
Part-time/flex job/sick listed	6 (12)	12 (24)
Student	12 (24)	5 (10)
Unemployed/retired	6 (12)	5 (10)
Previous shoulder treatment? (yes %)	31 (62)	37 (74)
Physiotherapy exercise	26 (52)	30 (60)
Physiotherapy passive treatment	18 (36)	26 (52)
Chiropractic	8 (16)	8 (16)
Analgesic medication (prescribed)	11 (22)	8 (16)
Other treatment	15 (30)	12 (24)
steroid injection	9 (18)	9 (18)
surgery	1 (2)	5 (10)
<u>Secondary self-reported outcomes</u>		
WOSI Physical symptoms (scale 0–1000)	469.0 (182.1)	474.8 (179.6)
WOSI Sports/recreation/work (scale 0–400)	211.2 (96.1)	192.2 (95.8)
WOSI Lifestyle (scale 0–400)	185.9 (91.9)	174.6 (77.3)
WOSI Emotions (scale 0–300)	205.4 (62.9)	200.6 (51.5)
Shoulder pain past seven days (scale 0-10)		
Lowest rating	2.4 (2.2)	2.4 (1.9)
Highest rating	6.5 (2.7)	6.0 (2.2)
Average rating	4.1 (2.2)	3.9 (2.1)
Discomfort due to mechanical shoulder symptoms past seven days (scale 0-10)		
Lowest rating	2.4 (2.3)	2.5 (2.1)
Highest rating	4.9 (2.4)	4.4 (2.7)
Average rating	3.7 (2.1)	3.2 (2.1)
Patient-Specific Functional Scale (scale 0-10)	3.9 (2.1)	3.9 (1.7)
Checklist Individual Strength (scale 8-56)	37.2 (9.8)	36.9 (11.4)
COOP/WONCA (scale 6-30)	15.0 (3.5)	13.9 (3.7)
Tampa Scale of Kinesiophobia (scale 11-44)	23.4 (5.2)	22.1 (5.8)
EQ-5D-5L (scale <0-1)	0.67 (0.16)	0.72 (0.11)
EQ-VAS (scale 0-100)	58.9 (21.2)	70.4 (16.5)
<u>Secondary objective outcomes</u>		
Range of motion (˚)		
Internal rotation passive	71 (19)	68 (17)
Internal rotation active	68 (19)	65 (18)
External rotation passive	100 (23)	105 (23)
External rotation active	97 (22)	102 (21)
Isometric shoulder torque strength (Nm/kg)		
Scaption	0.45 (0.20)	0.45 (0.22)
Internal rotation	0.33 (0.15)	0.33 (0.16)
External rotation	0.25 (0.10)	0.24 (0.11)
Proprioception in flexion (error ˚)		
Low range,	5.1 (3.2)	4.4 (2.6)

Mid-range	4.1 (2.5)	3.9 (2.2)
Shoulder instability and laxity tests (positive %)		
Shoulder flexion test‡, positive = yes	33 (66)	30 (60)
Shoulder rotation test, positive >180˚	20 (40)	20 (40)
Apprehension test†, positive = yes	36 (72)	38 (76)
Relocation test*, positive = yes	27 (54)	29 (58)
Release test*, positive = yes	24 (48)	21 (42)
Load and shift anterior ‡, positive 2-3	38 (76)	44 (88)
Load and shift posterior ‡, positive 2-3	19 (38)	14 (28)
Sulcus sign, positive >1 cm	43 (86)	46 (92)
Gagey‡, positive >105˚	36 (72)	44 (88)
Rotés Queról‡, positive > 90˚	26 (52)	22 (44)

Continuous data are presented as mean or median with 95% confidence interval (CI), and categorical variables are presented as frequency % (95% CI).

*Relocation and release tests were only performed on patients with a positive apprehension test.

† Of 74 patients with a positive apprehension test, 40 patients reported pain, 20 patients reported apprehension, and 14 patients reported both pain and apprehension.

‡ Of 100 patients, 17 patients were unable to complete the shoulder flexion test, 8 the Gagey test, 6 the Rotés Queról test, 1 the load and shift anterior test, and 3 the load and shift posterior test, resulting in the test scores for these patients were interpreted as negative.

Abbreviations: CIS, Checklist Individual Strength; COOP/WONCA, Dartmouth Primary Care Cooperative Research Network/World Organization of National Colleges, Academies and Academic Associations of General Practitioners/Family Physicians; EQ-5D-5L, European Quality of life - 5 Dimensions – Five-Level; IPAQ, International Physical Activity Questionnaire; NPRS, Numeric Pain Rating Scale; VAS, Visual Analogue Scale; WOSI, Western Ontario Shoulder Instability Index.

Supplementary file 2. Table. Self-reported pain medication and other treatments received during the 16-week intervention (as observed)

	LIGHT	**HEAVY**	**Between-Group Risk Difference or Median Difference ([a]) with 95% CI (unadjusted)**
Pain medication for index shoulder			
Week 1			
Number of participants (n)	48	48	
Use of pain medication (n (%))	11 (22.9)	9 (18.8)	-4 (-20, 12)
No pills	38 (79)	39 (81)	2 (-14, 18)
< 1 pills/day	3 (6)	6 (13)	8 (-4, 20)
1-4 pills/day	4 (8)	2 (4)	-4 (-14, 5)
> 4 pills/day	3 (6)	1 (2)	-4 (-12, 4)
Type of pain medication			
Paracetamol	10 (20.8)	7 (14.6)	-6 (-21, 9)
NSAIDs	6 (12.5)	2 (4.2)	-8 (-19, 3)
Other	1 (2.1)	2 (4.2)	2 (-5, 9)
Days of pain medication use (median, 95% CI)*	4 (2.7, 7)	2 (1, 2.9)	**-2 (-3.5, -0.5)**
Week 16			
Number of participants (n)	42	41	
Use of pain medication (n (%))	5 (11.9)	4 (9.8)	-2 (-16, 11)
No pills	38 (90)	37 (90.2)	-2 (-13, 12)
< 1 pills/day	2 (5)	1 (2.4)	-2 (-10, 6)
1-4 pills/day	2 (5)	2 (5)	0 (-9, 9)
> 4 pills/day	0 (0)	1 (2.4)	2 (-2, 7)
Type of pain medication			
Paracetamol	3 (7)	4 (10)	3 (-9, 15)
NSAIDs	2 (5)	1 (2)	-2 (-10, 6)
Other	2 (5)	2 (5)	0 (-9, 9)
Days of pain medication use (median, 95% CI)*	7 (1, 7)	4 (1, 7)	-3 (-16, 10)
Other treatments received			
Number of participants	49	48	
Sought GP during the 16-week intervention period (n (%)) because of the affected shoulder	7 (14.3)	5 (10.4)	-4 (-17, 9)
Received other treatment(s) for the affected shoulder (n (%))	14 (28.6)	11 (22.9)	-6 (-23, 12)
No other treatment	35 (71.4)	37 (77.1)	6 (-12, 23)
Physiotherapy (exercises)	0 (0.0)	2 (4.2)	4 (-1, 10)
Physiotherapy (stretch, ultrasound, massage)	4 (8.2)	2 (4.2)	-4 (-14, 6)
Professional massage	5 (10.2)	5 (10.4)	0 (-12, 12)
Chiropractor	3 (6.1)	1 (2.1)	-4 (-12, 4)
Acupuncture	1 (2.0)	2 (4.2)	2 (-5, 9)
Pain medication prescribed by GP	2 (4.1)	1 (2.1)	-2 (-9, 5)
Other	8 (16.3)	3 (6.3)	-10 (-22, 2)

Abbreviations: CI, confidence interval; GP, General practitioner; NSAIDs, Non-steroidal anti-inflammatory drugs.
* Based on the proportion of patients reporting use of pain medication.
Statistically significant results (p<0.05) are marked with bold.

Supplementary file 3. Table. Outcomes at 16-week follow-up for HEAVY and LIGHT presented for sensitivity analysis using intention-to-treat baseline value varied forward (ITT BVCF) and the per protocol (PP) analysis (multiple data imputation) for patients having satisfactory adherence to the interventions.

	Total no. of assessments (LIGHT/HEAVY) *	**Mean at 16 weeks in LIGHT** (95% CI) n (ITT) = 50 n (per protocol) = 33	**Mean at 16 weeks in HEAVY** (95% CI) n (ITT) = 50 n (per protocol) = 34	**Between-Group difference at 16 weeks (crude)** (95% CI)	**Between-Group difference at 16 weeks (adjusted)** † (95% CI)
Primary outcome measure					
WOSI total (scale 0-2100)					
ITT BVCF	96/97	834.4 (722.3, 946.5)	616.1 (495.2, 737.1)	**-218.3 (-383.3, -53.3)**	**-198.7 (-335.3, -62.1)**
PP	66/68	725.1 (597.8, 852.4)	475.0 (350.6, 599.4)	**-250.0 (-424.7, -75.3)**	**-250.7 (-323.4, -178.0)**
Secondary self-reported outcomes					
WOSI Physical symptoms (scale 0–1000)					
ITT BVCF	96/97	360.2 (302.8, 417.6)	283.5 (228.7, 338.3)	-76.7 (-155.1, 1.7)	**-78.9 (-142.8, -15.0)**
PP	66/68	307.5 (239.9, 375.1)	216.5 (161.0, 272.0)	**-91.0 (-176.6, -5.4)**	**-96.8 (-140.3, -53.3)**
WOSI Sports/recreation/work (scale 0–400)					
ITT BVCF	96/97	158.8 (131.9, 185.6)	110.7 (82.4, 138.9)	**-48.1 (-86.6, -9.6)**	**-39.4 (-70.6, -8.1)**
PP	66/68	140.2 (108.9, 171.6)	83.7 (54.4, 113.0)	**-56.5 (-98.6, -14.4)**	**-50.3 (-83.0, -17.5)**
WOSI Lifestyle (scale 0–400)					
ITT BVCF	96/97	141.0 (116.4, 165.7)	97.5 (72.0, 123.0)	**-43.5 (-78.6, -8.5)**	**-36.9 (-59.7, -14.1)**
PP	66/68	118.2 (89.1, 147.3)	74.2 (47.6, 100.7)	**-44.0 (-82.7, -5.4)**	**-49.7 (-65.1, -34.3)**
WOSI Emotions (scale 0–300)					
ITT BVCF	96/97	169.3 (150.2, 188.4)	121.7 (99.6, 143.8)	-50.0 (-79.9, -20.0)	-46.0 (-67.4, -24.6)
PP	66/68	159.2 (135.4, 182.8)	100.6 (76.3, 125.0)	-58.5 (-91.8, -25.2)	-56.2 (-71.6, -40.8)
Shoulder pain last 7 days (scale 0-10)					
Lowest rating					
ITT BVCF	95/97	1.3 (0.8, 1.8)	1.1 (0.6, 1.6)	-0.3 (-1.1, 0.4)	-0.4 (-1.1, 0.3)
PP	66/68	0.8 (0.4, 1.3)	0.4 (0.2, 0.7)	-0.4 (-0.9, 0.1)	-0.5 (-1.0, 0.0)
Highest rating					
ITT BVCF	95/97	4.0 (3.3, 4.8)	2.8 (2.1, 3.5)	**-1.4 (-2.4, -0.3)**	**-1.1 (-2.0, -0.2)**
PP	66/68	3.2 (2.5, 3.9)	1.8 (1.2, 2.4)	**-1.4 (-2.2, -0.5)**	**-1.2 (-1.8, -0.6)**
Average rating					
ITT BVCF	95/97	2.3 (1.7, 2.8)	1.7 (1.1, 2.3)	-0.7 (-1.5, 0.2)	-0.6 (-1.6, 0.3)
PP	66/68	1.6 (1.1, 2.1)	0.9 (0.5, 1.2)	-0.8 (-1.4, -0.1)	-0.8 (-1.2, -0.3)

Discomfort due to mechanical symptoms last 7 days (scale 0-10)					
Lowest rating					
ITT BVCF	95/97	1.3 (0.9, 1.6)	1.1 (0.7, 1.6)	-0.2 (-0.8, 0.5)	-0.2 (-0.9, 0.4)
PP	66/68	1.1 (0.7, 1.6)	0.6 (0.3, 1.0)	-0.5 (-1.1, 0.1)	-0.5 (-1.0, 0.0)
Highest rating					
ITT BVCF	95/97	3.0 (2.4, 3.6)	2.2 (1.6, 2.8)	-0.9 (-1.8, 0.0)	**-0.7 (-1.3, -0.05)**
PP	66/68	2.6 (1.9, 3.3)	1.6 (1.0, 2.3)	**-1.0 (-1.9, -0.002)**	**-0.8 (-1.6, -0.02)**
Average rating					
ITT BVCF	95/97	1.9 (1.5, 2.4)	1.5 (1.0, 2.1)	-0.6 (-1.3, 0.2)	-0.4 (-1.0, 0.2)
PP	66/68	1.6 (1.0, 2.2)	0.9 (0.4, 1.4)	-0.7 (-1.4, 0.1)	-0.5 (-1.3, 0.2)
Patient-Specific Functional Scale (scale 0-10)					
ITT BVCF	95/97	5.4 (4.7, 6.1)	5.7 (5.0, 6.5)	0.3 (-0.8, 1.3)	0.3 (-0.7, 1.4)
PP	66/68	6.1 (5.4, 6.9)	6.0 (5.1, 6.9)	-0.1 (-1.3, 1.0)	0.2 (-0.8, 1.2)
Checklist Individual Strength (scale 8-56)					
ITT BVCF	95/97	33.1 (29.6, 36.6)	30.1 (26.8, 33.4)	-3.0 (-7.8, 1.8)	-2.8 (-6.4, 0.8)
PP	66/68	29.2 (25.0, 33.5)	26.4 (23.3, 29.5)	-2.8 (-8.0, 2.4)	-1.9 (-6.3, 2.5)
COOP/WONCA (scale 6-30)					
ITT BVCF	94/97	14.3 (13.1, 15.5)	12.9 (11.7, 14.1)	-1.4 (-3.0, 0.3)	-0.6 (-1.7, 0.4)
PP	66/68	13.1 (11.7, 14.5)	11.4 (10.5, 12.4)	-1.6 (-3.3, 0.04)	-1.1 (-2.5, 0.4)
Tampa Scale of Kinesiophobia, (scale 11-44)					
ITT BVCF	94/97	22.4 (20.7, 24.1)	20.4 (18.8, 22.0)	-2.1 (-4.4, 0.3)	**-1.1 (-2.1, -0.02)**
PP	66/68	21.5 (19.6, 23.4)	19.6 (17.9, 21.3)	-1.9 (-4.4, 0.6)	**-1.6 (-2.4, -0.9)**
EQ-5D-5L, (scale <0-1)					
ITT BVCF	94/97	0.74 (0.70, 0.78)	0.79 (0.76, 0.83)	0.05 (-0.004, 0.1)	0.03 (-0.008, 0.06)
PP	66/68	0.78 (0.74, 0.81)	0.83 (0.80, 0.87)	**0.06 (0.02, 0.10)**	**0.06 (0.01, 0.10)**
EQ-VAS (scale 0-100)					
ITT BVCF	94/97	68.8 (63.7, 73.9)	74.4 (69.7, 79.2)	5.6 (-1.4, 12.6)	-0.4 (-7.2, 6.3)
PP	66/68	73.4 (68.2, 78.6)	80.6 (76.9, 84.4)	**7.2 (0.8, 13.6)**	2.4 (-4.2, 8.9)
<u>Secondary objective outcomes</u>					
Range of motion (˚)					
Internal rotation passive					
ITT BVCF	87/90	71.5 (66.6, 76.4)	69.6 (65.1, 74.1)	-1.9 (-8.5, 4.8)	0.4 (-2.1, 3.0)
PP	63/66	75.9 (70.0, 81.8)	68.1 (62.5, 73.8)	-7.7 (-15.6, 0.1)	-3.0 (-6.6, 0.5)
Internal rotation active					
ITT BVCF	87/90	67.9 (63.4, 72.5)	70.2 (66.2, 74.2)	2.3 (-3.8, 8.4)	**4.2 (0.4, 8.0)**
PP	63/66	71.0 (65.6, 76.3)	69.7 (64.9, 74.4)	-1.3 (-8.2, 5.6)	2.7 (-4.0, 9.3)
External rotation passive					
ITT BVCF	87/90	103.7 (96.2, 111.2)	107.2 (100.8, 113.5)	3.5 (-6.3, 13.3)	0.4 (-9.5, 10.3)
PP	63/66	110.2 (104.0, 116.3)	108.3 (100.9, 115.7)	-1.5 (-13.2, 10.2)	-1.8 (-10.8, 7.1)

External rotation active					
ITT BVCF	87/90	99.2 (92.7, 105.7)	106.4 (100.9, 111.9)	7.2 (-1.4, 15.7)	3.9 (-3.2, 10.9)
PP	63/66	104.9 (99.8, 110.1)	106.7 (100.0, 113.5)	1.8 (-6.0, 9.6)	1.8 (-8.1, 11.6)
Isometric shoulder torque strength (Nm/kg)					
Scaption					
ITT BVCF	87/90	0.46 (0.41, 0.52)	0.51 (0.44, 0.57)	0.04 (-0.04, 1.3)	**0.04 (0.02, 0.07)**
PP	63/66	0.51 (0.44, 0.59)	0.56 (0.47, 0.64)	0.04 (-0.07, 0.16)	0.07 (-0.002, 0.13)
Internal rotation					
ITT BVCF	87/90	0.36 (0.31, 0.40)	0.35 (0.30, 0.40)	-0.01 (-0.07, 0.06)	0.002 (-0.02, 0.02)
PP	63/66	0.39 (0.33, 0.45)	0.38 (0.32, 0.45)	-0.01 (-0.10, 0.08)	0.01 (-0.03, 0.04)
External rotation					
ITT BVCF	87/90	0.25 (0.22, 0.27)	0.26 (0.23, 0.30)	0.02 (-0.03, 0.06)	0.02 (-0.01, 0.06)
PP	63/66	0.26 (0.23, 0.29)	0.29 (0.24, 0.34)	0.03 (-0.03, 0.08)	0.03 (-0.02, 0.08)
Proprioception in flexion (error ˚)					
Low range					
ITT BVCF	87/90	4.6 (3.8, 5.4)	4.8 (3.9, 5.7)	0.2 (-0.9, 1.4)	0.7 (-0.4, 1.7)
PP	63/66	4.5 (3.5, 5.5)	5.1 (3.8, 6.5)	0.6 (-1.0, 2.2)	1.1 (-0.5, 2.7)
Mid-range					
ITT BVCF	86/90	3.6 (3.0, 4.1)	4.2 (3.3, 5.1)	0.6 (-0.4, 1.7)	0.7 (-0.5, 1.8)
PP	63/66	3.2 (2.4, 3.9)	4.4 (3.1, 5.6)	1.2 (-0.2, 2.6)	1.1 (-1.0, 3.3)
Shoulder instability and laxity tests (positive %) §					
Shoulder flexion test, positive = yes					
ITT BVCF	87/90	72 (58, 83)	62 (48, 74)	0.60 (0.12, 3.09)	0.63 (0.27, 1.47)
PP	63/66	79 (65, 93)	61 (44, 78)	0.42 (0.14, 1.26)	0.38 (0.06, 2.31)
Shoulder rotation test, positive >180˚					
ITT BVCF	87/90	54 (40, 67)	42 (29, 56)	0.62 (0.28, 1.36)	0.45 (0.16, 1.24)
PP	63/66	62 (45, 79)	40 (23, 57)	0.41 (0.15, 1.15)	**0.35 (0.14, 0.90)**
Apprehension test, positive = yes					
ITT BVCF	87/90	72 (58, 83)	64 (50, 76)	0.69 (0.30, 1.61)	0.53 (0.27, 1.02)
PP	63/66	64 (47, 80)	65 (49, 82)	1.08 (0.39, 2.95)	0.75 (0.38, 1.48)
Relocation test ‖, positive = yes					
ITT BVCF	87/90	56 (42, 69)	44 (31, 58)	0.62 (0.28, 1.36)	0.49 (0.32, 0.77)
PP	63/66	52 (34, 70)	48 (30, 65)	0.84 (0.31, 2.22)	0.71 (0.41, 1.25)

Release test ‖, positive = yes					
ITT BVCF	87/90	50 (36, 64)	34 (22, 48)	0.52 (0.23, 1.15)	0.49 (0.20, 1.19)
PP	63/66	45 (27, 63)	42 (25, 59)	0.86 (0.32, 2.32)	0.79 (0.29, 2.13)
Load and shift anterior, positive 2-3					
ITT BVCF	87/90	68 (54, 79)	68 (54, 79)	1 (0.43, 2.32)	0.65 (0.29, 1.45)
PP	63/66	68 (51, 85)	65 (49, 82)	0.89 (0.31, 2.53)	0.60 (0.22, 1.64)
Load and shift posterior, positive 2-3					
ITT BVCF	87/90	30 (19, 44)	20 (11, 34)	0.58 (0.23, 1.46)	0.67 (0.22, 2.03)
PP	63/66	30 (14, 46)	15 (3, 28)	0.43 (0.13, 1.44)	0.46 (0.10, 2.13)
Sulcus sign, positive >1 cm					
ITT BVCF	87/90	84 (71, 92)	86 (73, 93)	1.17 (0.39, 3.51)	1.11 (0.44, 2.79)
PP	63/66	85 (72, 97)	85 (72, 97)	0.99 (0.26, 3.83)	1.08 (0.30, 4.00)
Gagey, positive >105˚					
ITT BVCF	87/90	88 (76, 95)	92 (80, 97)	1.57 (0.41, 5.93)	0.70 (0.39, 1.28)
PP	63/66	93 (84, 103)	91 (80, 101)	0.68 (0.10, 4.57)	0.36 (0.10, 1.36)
Rotés Queról, positive > 90˚					
ITT BVCF	87/90	60 (46, 73)	52 (38, 66)	0.72 (0.33, 1.60)	0.73 (0.27, 1.96)
PP	63/66	52 (34, 70)	51 (33, 68)	0.94 (0.35, 2.50)	0.62 (0.18, 2.10)
Global Perceived Effect ‡ §					
(% rated important effect postintervention)					
Physical symptoms					
PP	33/34	54.5 (37.4, 70.7)	79.4 (62.3, 90.0)	**OR 3.2 (1.1, 9.4)**	**OR 3.6 (1.7, 7.6)**
Sports/recreation/work					
PP	33/34	48.5 (32.0, 65.4)	64.7 (47.2, 79.0)	OR 1.9 (0.7, 5.2)	**OR 2.0 (1.0, 4.1)**
Lifestyle					
PP	33/34	51.5 (34.6, 68.0)	64.7 (47.2, 79.0)	OR 1.7 (0.6, 4.6)	OR 1.8 (0.7, 4.7)
Emotions					
PP	33/34	45.5 (29.3, 62.6)	64.7 (47.2, 79.0)	OR 2.2 (0.8, 5.9)	OR 2.2 (0.7, 6.3)

* For BVCF, there were 100 possible assessments for each group (50 at baseline and 50 at 16 weeks follow-up), except for Global Perceived Effect, which had 50 possible assessments for each group. For per protocol, there were 66 and 68 possible assessments for LIGHT and HEAVY, respectively, except for Global Perceived Effect which had 33 (LIGHT) and 34 (HEAVY) possible assessments.

† The results are adjusted for baseline score, age, sex, and the clustering of physiotherapy clinic

‡ No data imputation

§ Proportions of a positive test in % (95% CI) and odds ratio (OR) for between-group differences with group LIGHT as reference.

‖ Relocation and release tests were only performed on patients with a positive apprehension test.

Abbreviations: CI, Confidence Interval; CIS, Checklist Individual Strength; COOP/WONCA, Dartmouth Primary Care Cooperative Research Network/World Organization of National Colleges, Academies and Academic Associations of General Practitioners/Family Physicians; EQ-5D-5L, European Quality of Life - Five Dimensions – Three Level; NPRS, Numeric Pain Rating Scale; VAS, Visual Analogue Scale; WOSI, Western Ontario Shoulder Instability Index.

Statistically significant results (p<0.05) are marked with bold.

Supplementary file 4. Table. Outcomes at 16-week follow-up for HEAVY and LIGHT.

	Total no. of assessments (LIGHT/HEAVY) *	**Mean at 16 weeks in LIGHT** (95% CI) n = 50	**Mean at 16 weeks in HEAVY** (95% CI) n = 50	**Between-Group difference at 16 weeks (crude risk ratio)** (95% CI)	**Between-Group difference at 16 weeks (adjusted risk ratio) †** (95% CI)
Shoulder instability and laxity tests (positive %) §					
Shoulder flexion test, positive = yes	87/90	78 (64, 91)	62 (47, 76)	0.79 (0.49, 1.29)	0.84 (0.62, 1.14)
Shoulder rotation test, positive >180˚	87/90	62 (47, 76)	42 (28, 56)	0.68 (0.38, 1.19)	**0.68 (0.49, 0.95)**
Apprehension test, positive = yes	87/90	70 (55, 85)	62 (48, 76)	0.89 (0.55, 1.44)	0.86 (0.69, 1.06)
Relocation test‖, positive = yes	87/90	55 (38, 72)	44 (30, 58)	0.81 (0.45, 1.45)	0.78 (0.60, 1.01)
Release test‖, positive = yes	87/90	50 (32, 68)	37 (23, 51)	0.74 (0.40, 1.38)	0.74 (0.48, 1.16)
Load and shift anterior, positive 2-3	87/90	68 (52, 84)	62 (47, 77)	0.91 (0.55, 1.51)	0.84 (0.66, 1.06)
Load and shift posterior, positive 2-3	87/90	28 (13, 44)	18 (7, 29)	0.65 (0.27, 1.57)	0.73 (0.32, 1.67)
Sulcus sign, positive >1 cm	87/90	84 (68, 93)	85 (70, 93)	1.00 (0.64, 1.55)	1.00 (0.82, 1.23)
Gagey, positive >105˚	87/90	92 (85, 100)	90 (78, 100)	0.97 (0.64, 1.47)	0.95 (0.84, 1.07)
Rotés Queról, positive > 90˚	87/90	63 (48, 77)	55 (41, 69)	0.88 (0.52, 1.47)	1.00 (0.78, 1.28)
Global Perceived Effect ‡ §					
(% rated important effect postintervention)					
Physical symptoms	45/47	44 (31, 59)	64 (49, 76)	1.44 (0.82, 2.53)	**1.46 (1.06, 2.01)**
Sports/recreation/work	45/47	38 (25, 53)	51 (37, 65)	1.35 (0.73, 2.52)	1.36 (0.90, 2.06)
Lifestyle	45/47	44 (31, 59)	55 (41, 69)	1.24 (0.69, 2.23)	1.26 (0.78, 2.03)
Emotions	45/47	40 (27, 55)	51 (37, 65)	1.28 (0.69, 2.35)	1.27 (0.70, 2.30)

* There were 100 possible assessments for each group (50 at baseline and 50 at 16 weeks follow-up), except for Global Perceived Effect which had 50 possible assessments for each group.

† The results are adjusted for baseline score of the variable of interest, age, sex, and the clustering around clinic.

‡ No data imputation

§ Proportions of positive test in % (95% CI) and risk ratio for between-group differences with group LIGHT as reference.

‖ Relocation and release tests were only performed on patients with a positive apprehension test.

Abbreviations: CI, Confidence Interval; CIS, Checklist Individual Strength; COOP/WONCA, Dartmouth Primary Care Cooperative Research Network/World Organization of National Colleges, Academies and Academic Associations of General Practitioners/Family Physicians; EQ-5D-5L, European Quality of Life - Five Dimensions – Three Level; NPRS, Numeric Pain Rating Scale; VAS, Visual Analogue Scale; WOSI, Western Ontario Shoulder Instability Index.

Statistically significant results ($p<0.05$) are marked with bold.

Supplementary file 5. Table. Adverse Events (specific, serious or minor, and withdrawals due to adverse events), and crude difference between risks and medians were calculated with 95% Confidence Intervals based on the "per protocol' data while still respecting the original group allocation, from baseline to 16-week follow-up for HEAVY vs LIGHT in patients with hypermobility spectrum disorder and shoulder complaints

Adverse events	**LIGHT (n = 33)**	**HEAVY (n = 34)**	**Between-Group Risk Difference or Median difference with 95% CI (unadjusted)**
Number of patients reporting serious adverse events*	0 (0)	0 (0)	0 (0, 0)
Number of patients reporting minor adverse events (n (%))	20 (61)	21 (62)	1 (-22, 24)
Index shoulder			
- Muscle soreness	15 (45)	17 (50)	5 (-19, 28)
- Shoulder is locked	2 (6)	1 (3)	-3 (-13, 7)
- Subluxation	3 (9)	1 (3)	-6 (-17, 5)
- Dislocation	0 (0)	1 (3)	3 (-3, 9)
- Persistent worsening of symptoms	6 (18)	5 (15)	-3 (-21, 14)
Other sites than index shoulder			
- Headache	6 (18)	11 (32)	14 (-6, 35)
"Other" minor events related to index shoulder or other sites	14 (42)	13 (38)	-4 (-28, 19)
Number of minor adverse events (median, (95% CI) †	1 (0, 4.3)	2 (0, 3.2)	1 (-0.6, 2.6)
Index shoulder			
- Muscle soreness	0 (0, 1)	0.5 (0, 2)	0.5 (-0.04, 1.04)
- Shoulder is locked	0 (0, 0)	0 (0, 0)	0 (0, 0)
- Subluxation	0 (0, 0)	0 (0, 0)	0 (0, 0)
- Dislocation	0 (0, 0)	0 (0, 0)	0 (0, 0)
- Persistent worsening of symptoms	0 (0, 0)	0 (0, 0)	0 (0, 0)
Other sites than index shoulder			
- Headache	0 (0, 0)	0 (0, 0.2)	0 (0, 0)
"Other" minor events related to index shoulder or other sites	0 (0, 1)	0 (0, 1)	0 (0, 0)

This table includes all adverse events that occurred during the 16-week study period, but which did not necessarily have a causal relationship with the treatment administered. *Serious adverse events are unexpected but cover death, life-threatening events, disability, and permanent damage.

† For each patient, each adverse event could count 0 to 16 times corresponding with the 16-week intervention period.

Supplementary file 6. Table. The adjusted (age, sex, clustering around clinic) risk difference using margins after fitting a logistic regression model for adverse events with 95% Confidence Intervals based on the 'as observed' data while still respecting the original group allocation, from baseline to 16-week follow-up for HEAVY vs LIGHT in patients with hypermobility spectrum disorder

Adverse events	**LIGHT (n = 46)**	**HEAVY (n = 45)**	**Model-based standardisation:** Between-group risk differences adjusted for age, sex, and cluster by clinics
Number of patients reporting minor adverse events (n (%))	24 (52)	29 (64)	12 (-6, 29)
Index shoulder			
- Muscle soreness	17 (37)	25 (56)	18 (-5, 42)
- Shoulder is locked	3 (4)	2 (4)	-2 (-10, 5)
- Subluxation	3 (7)	1 (2)	-5 (-10, 0)
- Dislocation	0 (0)	1 (2)	Not possible due to no events in the LIGHT group
- Persistent worsening of symptoms	8 (17)	8 (18)	0 (-20, 21)
Other sites than index shoulder			
- Headache	9 (20)	18 (40)	20 (-2, 42)
"Other" minor events related to index shoulder or other sites	18 (39)	19 (42)	2 (-27, 31)

This table includes all adverse events that occurred during the 16-week study period but did not necessarily have a causal relationship with the treatment administered.